The Global Cholangiocarcinoma Alliance (GCA) – World Cholangiocarcinoma Day 2022​

Cholangiocarcinoma (CCA), also known as bile duct cancer, is a cancer with a high mortality rate. Although it is considered rare, the worldwide incidence of this devastating cancer is increasing. The epidemiology of the disease varies between regions, with risk factors well defined in some areas and poorly in others.​

The collective voice of the GCA will mark World Cholangiocarcinoma Day on February 12, 2022. The GCA has united to establish a global community in CCA through international collaborations and it works towards improving the future for patients with CCA across the globe.​

The GCA is asking people to get involved on World CCA Day in 2022 to help us ‘See CCA’ and raise awareness. Details of how to get involved and resources can be found here. ​

​Everyone can make a difference on World CCA Day and beyond by posting on social media about CCA using the hashtags #WorldCCADay and #SeeCCA on February 12, 2022. Get involved online and offline and encourage colleagues and friends to do so too.​

​“World Cholangiocarcinoma Day – one day each year when organisations and individuals from around the world join together in a nationally neutral way under the global symbol of the #WorldCCADay icon, to raise the awareness of cholangiocarcinoma and to collaborate internationally for an improved future for cholangiocarcinoma patients everywhere.” - Helen Morement, Co-Chair of the GCA

You can support the goals of the GCA further by signing the pledge to support the CCA community and continuing to raise awareness globally. You can find the pledge here. We will use these pledges to continue to build a network of informed supporters who will strengthen and expand our reach in establishing a global voice in CCA and ensure our vision becomes a reality. ​

The GCA is supported by Scientific Education Support (SES) who are the secretariat. SES supports the building of communities and networks to facilitate education through collaboration, ensuring that patients have access to the latest support and treatment options. ​

For more information on the GCA, please all press and media enquiries, please Vincenzo Cardinale, European Network for the Study of Cholangiocarcinoma, Italy​

Associate Professor Jesper Andersen, European Network for the Study of Cholangiocarcinoma, Denmark​

Associate Professor Jesus Bañales, European Network for the Study of Cholangiocarcinoma, Spain​

Dr Shijie Cai, University of Oxford and Xiamen Tumor Hospital, United Kingdom and China​

European Network for the Study of Cholangiocarcinoma – www.enscca.org/